Zura Bio's Phase 2 TibuSHIELD trial of tibulizumab in hidradenitis suppurativa failed its primary endpoint — no benefit over placebo in reducing abscesses and inflammatory nodules at Week 16 — and missed key secondary endpoints. The company is discontinuing development in this indication, though its systemic sclerosis and polymyalgia rheumatica programs continue. Zura holds $187.7M in cash, enough to fund operations through at least the end of 2028.
Useful?